FDA Gives Approval For Novartis'' Tafinlar Mekinist Broadens BRAF|MEK Cancer Combo Use
The FDA granted accelerated approval to Novartis AG''s (NYSE: NVS ) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF V600E mutation. The patient must have progressed following prior therapy and have no alternative treatment options. The combo is already approved for BRAF mutated non-small cell lung cancer, melanoma, and thyroid cancer. Individuals … Full story available on Benzinga.com
FDA Gives Approval For Novartis'' Tafinlar Mekinist Broadens BRAF|MEK Cancer Combo Use
The FDA granted accelerated approval to Novartis AG''s (NYSE: NVS ) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF V600E mutation. The patient must have progressed following prior therapy and have no alternative treatment options. The combo is already approved for BRAF mutated non-small cell lung cancer, melanoma, and thyroid cancer. Individuals … Full story available on Benzinga.com